JPWO2020144664A5

JPWO2020144664A5 -

Info

Publication number: JPWO2020144664A5
Application number: JP2021539946A
Authority: JP
Publication date: 2023-01-25

Claims

A system for removing cytokines and other substances from the blood of a subject in a closed fluid circuit, said system comprising a plasma separator, an adsorption chamber disposed within said circuit, and a binding chamber. wherein said binding chamber comprises a material comprising 50-70% by weight activated carbon and 30-50% by weight non-ionic resin, said system comprising:
(i) passing venous blood from the subject through the plasma separator, wherein the plasma separator is configured to separate the blood into blood cells and plasma;
(ii) passing the plasma received directly from the plasma separator through the adsorption chamber disposed in the circuit to form treated plasma , wherein the material in the adsorption chamber comprises the plasma configured to adsorb cytokines therein to form said treated plasma;
(iii) combining the treated plasma received directly from the adsorption chamber with the blood cells in the combining chamber, the combining chamber without exchanging any of the plasma with another fluid; configured to form treated blood, and wherein the treated blood from the circuit may be transfused directly into the subject, prior to completing the transfusion of the treated blood to the subject; , configured such that no fluid other than the subject's blood is added to the circuit;
A system effective and configured to carry out

The nonionic resin is at least one selected from the group consisting of nonionic aliphatic ester resins, nonionic polystyrene divinylbenzene resins, hydrophobic interaction chromatography agarose media, and other non-biosorbent resins. 2. The system of claim 1, comprising one resin material.

(i) the nonionic aliphatic ester resin is AMBERLITE® XAD-7HP ;
(ii) the nonionic polystyrene divinylbenzene resin is AMBERCHROM® GC300C, or
(iii) the activated carbon comprises at least one activated carbon material selected from the group consisting of uncoated coconut shell granulated carbon, uncoated organic granulated carbon, and uncoated synthetic carbon; System as described.

10. The adsorption chamber of claim 1, wherein the adsorption chamber is composed of a polymer selected from the group consisting of polycarbonate, polypropylene, lexan copolymer, polytetrafluoroethylene, and other medical grade polymers suitable for injection or blow molding. system.

The adsorption chamber is
a housing comprising a hollow tube having opposed open ends, said housing containing said activated carbon and a nonionic resin;
A porous membrane filter covering each end of the housing, each porous membrane filter containing the activated carbon and non-ionic resin within the housing while allowing the passage of the plasma during the performance of the method steps. a porous membrane filter that forms a barrier to maintain
an end cap attached to each end of the housing, each end cap holding its corresponding porous membrane filter in place and the end cap to the corresponding end of the housing; 2. The system of claim 1, comprising an end cap configured to maintain a seal therebetween.

(i) each end cap includes a groove molded around its inner circumference, said groove configured to facilitate mating of each end cap with said corresponding end of said housing; , optionally
said groove configured to receive an amount of adhesive, said adhesive deposited within said groove to assist in adhering said porous membrane filter to said end cap;
Another amount of adhesive is deposited between each endcap and its corresponding porous membrane filter to provide additional adhesion between the endcap and the corresponding end of the housing. ,
(ii) the ends of the housing are threaded and the corresponding end caps are also threaded to fit together; or
(iii) The system of claim 5 , wherein the housing is in the form of a tube comprising at least one of polypropylene, polytetrafluoroethylene, or other medical grade tubing material .

The adsorption chamber and/or the material within the adsorption chamber is coated with human serum albumin and an anticoagulant added to saline as a delivery solution prior to clinical use ; , sodium heparin and acid citrate dextrose solution ACD-A .

2. The system of claim 1, wherein said adsorption chamber is effective in removing toxins other than cytokines from said subject's blood.

A material comprising 50-70% by weight activated carbon and 30-50% by weight non-ionic resin, said material being used in a method of removing cytokines and other substances from the blood of a subject in a closed fluid circuit. A material in the adsorption chamber of a system according to any one of claims 1-8 for use.

Use of the system according to any one of claims 1 to 8 in a method of removing cytokines and other substances from the blood of a subject in a closed fluid circuit, said system being an extracorporeal plasma system. use of the system.

A material comprising 50-70% by weight of activated carbon and 30-50% by weight of a nonionic resin, said material of claims 1-8 for use in a method for therapeutic treatment of a subject. In an adsorption chamber of a system according to any one of the preceding claims, the method comprising:
passing venous blood from the subject through a plasma separator, thereby separating the blood into blood cells and plasma;
passing the plasma received from the plasma separator through an adsorption chamber disposed in the circuit to form treated plasma, wherein the material in the adsorption chamber adsorbs cytokines in the plasma; forming said processed plasma;
combining the processed plasma received directly from the adsorption chamber with the blood cells in a combining chamber to form processed blood without exchanging any of the plasma with another fluid;
transfusing the treated blood from the circuit directly into the subject, wherein prior to completion of the transfusion of the treated blood to the subject, a fluid other than the subject's blood is introduced into the circuit. removing cytokines and other substances from the blood of the subject without being added to the blood, thereby providing the therapeutic treatment to the subject.

The therapeutic treatment is sepsis, liver failure, viral infection, acute respiratory distress, renal failure, inflammation, poisoning, drug overdose, autoimmune disease, tick-borne disease, chemical or nerve agent exposure, burn bile duct obstruction, postoperative A disease selected from the group consisting of inflammation, bacterial infection, complications caused by smoke inhalation, complications as a result of any form of injury or trauma, and complications as a result of any form of cancer or cancer treatment. or to a state , optionally
(i) said autoimmune disease is selected from the group consisting of inflammatory arthritis, psoriasis, Crohn's disease, ulcerative colitis, inflammatory bowel disease, and uveitis; or
12. The material of use of claim 11, wherein (ii) said inflammation is treated using an age-defying anti-inflammatory application selected from the group consisting of cosmetic applications, pain applications, and discomfort applications .

12. The material of use according to claim 11, wherein said therapeutic treatment is administered through the use of standard venous access in an outpatient treatment setting.

12. The material for use according to claim 11, further comprising the step of introducing an anticoagulant into said circuit, optionally said anticoagulant is citrate dextrose solution ACD-D .

12. The material for use of claim 11 , further comprising removing toxins from the blood of the subject using the adsorption chamber.